TCW illustrated field note · 04
Retatrutide & heart rate
Read the trial finding without turning an average into a promise.
The guide, in text
What was studied
Retatrutide activates GIP, GLP-1 and glucagon receptors. It remains investigational and is not FDA approved.
The phase 2 finding
In the 2023 obesity trial, heart-rate increases were dose-dependent, peaked at 24 weeks and declined afterward.
The timeline matters
The trial does not support a universal peak at 4–8 weeks or a promise of returning to baseline by six months.
What an average cannot tell you
Individual responses differ. Improvements in other markers do not establish that a heart-rate change is harmless or prove cardiovascular benefit.
Symptoms deserve attention
Discuss a persistent resting-heart-rate change with a clinician. Chest pain, fainting or severe breathlessness require urgent medical care. Do not adjust an investigational drug using this graphic.
Sources + context
Source review: September 2026. Illustrations explain concepts; they do not verify products or replace individualized advice.